Suppr超能文献

NURR1与缺血性中风后重组组织型纤溶酶原激活剂治疗并发症的关系。

NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke.

作者信息

Merino-Zamorano Cristina, Hernández-Guillamon Mar, Jullienne Amandine, Le Béhot Audrey, Bardou Isabelle, Parés Mireia, Fernández-Cadenas Israel, Giralt Dolors, Carrera Caty, Ribó Marc, Vivien Denis, Ali Carine, Rosell Anna, Montaner Joan

机构信息

From the Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain (C.M.-Z., M.H.-G., M.P., I.F.-C., D.G., C.C., A.R., J.M.); INSERM UMR-S U919, GIP Cyceron, University of Caen, Caen, France (A.J., A.L.B., I.B., D.V., C.A.); and Neurovascular Unit, Department of Neurology, Vall d'Hebron Hospital, Barcelona, Spain (M.R., J.M.).

出版信息

Stroke. 2015 Feb;46(2):477-84. doi: 10.1161/STROKEAHA.114.006826. Epub 2014 Dec 11.

Abstract

BACKGROUND AND PURPOSE

Despite the effectiveness of recombinant tissue-type plasminogen activator (r-tPA) during the acute phase of ischemic stroke, the therapy remains limited by a narrow time window and the occurrence of occasional vascular side effects, particularly symptomatic hemorrhages. Our aim was to investigate the mechanisms underlying the endothelial damage resulting from r-tPA treatment in ischemic-like conditions.

METHODS

Microarray analyses were performed on cerebral endothelial cells submitted to r-tPA treatment during oxygen and glucose deprivation to identify novel biomarker candidates. Validation was then performed in vivo in a mouse model of thromboembolic stroke and culminated in an analysis in a clinical cohort of patients with ischemic stroke treated with thrombolysis.

RESULTS

The transcription factor NURR1 (NR4A2) was identified as a downstream target induced by r-tPA during oxygen and glucose deprivation. Silencing NURR1 expression reversed the endothelial-toxicity induced by the combined stimuli, a protective effect attributable to reduced levels of proinflammatory mediators, such as nuclear factor-kappa-beta 2 (NF-κ-B2), interleukin 1 alpha (IL1α), intercellular adhesion molecule 1 (ICAM1), SMAD family member 3 (SMAD3), colony stimulating factor 2 (granulocyte-macrophage; CSF2). The detrimental effect of delayed thrombolysis, in conditions in which NURR1 gene expression was enhanced, was confirmed in the preclinical stroke model. Finally, we determined that patients with stroke who had a symptomatic hemorrhagic transformation after r-tPA treatment exhibited higher baseline serum NURR1 levels than did patients with an asymptomatic or absence of cerebral bleedings.

CONCLUSIONS

Our results suggest that NURR1 upregulation by r-tPA during ischemic stroke is associated with endothelial dysfunction and inflammation and the enhancement of hemorrhagic complications associated to thrombolysis.

摘要

背景与目的

尽管重组组织型纤溶酶原激活剂(r-tPA)在缺血性卒中急性期具有疗效,但该疗法仍受限于狭窄的时间窗以及偶尔出现的血管副作用,尤其是症状性出血。我们的目的是研究在缺血样条件下r-tPA治疗导致内皮损伤的潜在机制。

方法

对在氧糖剥夺期间接受r-tPA治疗的脑内皮细胞进行微阵列分析,以识别新的生物标志物候选物。然后在血栓栓塞性卒中的小鼠模型中进行体内验证,并最终在接受溶栓治疗的缺血性卒中患者临床队列中进行分析。

结果

转录因子NURR1(NR4A2)被确定为r-tPA在氧糖剥夺期间诱导的下游靶点。沉默NURR1表达可逆转联合刺激诱导的内皮毒性,这种保护作用归因于促炎介质水平的降低,如核因子-κB2(NF-κ-B2)、白细胞介素1α(IL1α)、细胞间黏附分子1(ICAM1)、SMAD家族成员3(SMAD3)、集落刺激因子2(粒细胞-巨噬细胞;CSF2)。在临床前卒中模型中证实了在NURR1基因表达增强的情况下延迟溶栓的有害作用。最后,我们确定r-tPA治疗后出现症状性出血转化的卒中患者的基线血清NURR1水平高于无症状或无脑出血的患者。

结论

我们的结果表明,缺血性卒中期间r-tPA导致的NURR1上调与内皮功能障碍和炎症以及溶栓相关出血并发症的增加有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验